U.S.-listed shares of Novo Nordisk plunged 7% in intraday trading Thursday after rival Eli Lilly reported positive oral ...

The analyst highlights that Lilly’s drugs, Mounjaro and Zepbound, will likely keep gaining U.S. market share from Novo ...

Danish drugmaker Novo Nordisk said several hundred counterfeit units of its diabetes drug Ozempic were being distributed in ...

Pfizer’s announcement that it will stop developing its oral weight-loss drug gave shares of Wegovy maker Novo Nordisk and ...

U.S. pharma giant Eli Lilly And Co (NYSE:LLY) announced the launch of its popular weight loss drug Mounjaro (tirzepatide) in ...

Lilly shares are up 14.2% in response to the news, while shares of its rivals in the GLP-1 weight loss market, Novo Nordisk ( ...

Novo Nordisk, the producer of Ozempic, Wegovy and other medications, will invest 6.4 billion reais ($1.09 billion) in Brazil ...

Danish pharmaceutical company Novo Nordisk is set to launch its anti-diabetes and weight-loss drug Wegovy in India, aiming to ...

BMO Capital Markets downgraded Novo Nordisk (NYSE:NVO) to “Market Perform” from “Outperform” and cut its price target to $64, saying the Danish drugmaker’s early lead in the obesity drug market is ...

The tortoise (Eli Lilly) has caught the hare (Novo Nordisk), according to a report from BMO Capital Markets, which cites the superior commercial and clinical portfolios of the Indianapolis company ...

Novo Nordisk (NVO), the company behind Ozempic and Wegovy, announced that it will invest 6.4 billion reais (about $1.09 ...

We came across a bullish thesis on Novo Nordisk A/S (NVO) on Substack by Felix. In this article, we will summarize the bulls’ ...